An interventional study of Low tidal volume ventilation strategy and Intermediate tidal volume ventilation strategy in Cardiogenic Pulmonary Oedema, Acute Hypoxemic Respiratory Failure and Ventilator-Induced Lung Injury, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Some people with heart failure develop fluid buildup in the lungs and need a breathing machine while they are treated in an intensive care unit. The amount of air delivered with each breath may affect how quickly they recover.
The LOGICAL study will compare two ways of setting the breathing machine: delivering a lower or an intermediate amount of air with each breath. About 300 adults in intensive care units across Spain will be randomly assigned to one of these strategies.
The study aims to find out whether the lower amount of air increases the number of days patients are alive and breathing without the machine during the first 28 days after assignment. The researchers will also assess other outcomes, including survival and length of stay in the intensive care unit and hospital.
1,370 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.
This study's planned enrollment of 300 is above the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.
Browse Respiratory Insufficiency studies →Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 13 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Acute hypoxemic respiratory failure of cardiogenic origin, meeting all three of the following criteria:
Pulmonary congestion shown by at least one of the following:
Evidence of a cardiogenic origin shown by at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 ml/kg of predicted body weight. Tidal volume may be reduced to 4 ml/kg according to respiratory mechanics and clinical tolerance.
Procedure: Low tidal volume ventilation strategy
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining airway pressures within the protocol-defined safety limits.
Procedure: Intermediate tidal volume ventilation strategy
Volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 mL/kg of predicted body weight. Tidal volume may be reduced stepwise to 4 mL/kg according to respiratory mechanics and clinical tolerance.
Volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining plateau pressure below 30 cmH₂O and driving pressure below 15 cmH₂O.
Days Alive and Free of Invasive Mechanical Ventilation Through Day 28
Number of days from randomization through day 28 that a participant is alive and free of invasive mechanical ventilation. Participants who die before day 28 are assigned 0 days. Higher values indicate a more favorable outcome.
Time frame: From randomization through day 28
All-Cause Mortality at Day 28
Percentage of participants who die from any cause within 28 days after randomization.
Time frame: From randomization through day 28
Duration of Invasive Mechanical Ventilation
Time from randomization to successful liberation from invasive mechanical ventilation, defined as remaining free of invasive mechanical ventilation for at least 48 hours. Death before liberation will be considered a competing event in the analysis.
Time frame: From randomization until successful liberation, death, or day 90
No study locations are listed for this record.
Plan to share: Undecided — The investigators intend to explore sharing anonymized individual participant data after publication of the main results, subject to ethical approval, applicable data protection requirements, and assessment of re-identification risk. The specific data sets, access process, and availability period have not yet been determined.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 19 months is below that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación para la Investigación Biosanitaria del Principado de Asturias